Condition: Post ERCP Pancreatitis · Sponsor: Chinese University of Hong Kong
Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant morbidities and occasional mortalities. The use of rectall administered indomethacin and pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The comparative effectiveness of the two methods has however not been studied. It is argued that in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS insertion however believe that mechanical decompression of the pancreatic duct is critical in the prevention of pancreatitis. The investigators propose a multi-centre randomised controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk patients in the prevention of PEP.
This description comes directly from the study's public registry record.
James LAU, MD · 35051411 · laujyw@surgery.cuhk.edu.hk
RAYMOND TANG, MD · 35052640 · raymondtang@cuhk.edu.hk
Always discuss trial participation with your own doctor first.
| Endoscopy centre | Xi'an, Shaanxi, China | Recruiting |
| Eastern Hepatobiliary Surgery Hospital,Endoscopy centre | Shanghai, Shanghai Municipality, China | Recruiting |
| Endoscopy centre | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Endoscopy centre | Tianjin, Tianjin Municipality, China | Recruiting |
| Endoscopy centre | Hangzhou, Zhejiang, China | Recruiting |
| Endoscopy Centre, Prince of Wales Hospital | Hong Kong, Hong Kong, Hong Kong | Recruiting |
| 2. Chulalongkorn University and King Chulalongkorn Memorial Hospital | Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03713879